Overview

G-CSF for Granulocyte Donation

Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
0
Participant gender:
All
Summary
This study will examine the feasibility of giving cell growth stimulants to granulocyte donors the same day of donation rather than the day before. People who donate granulocytes (infection-fighting white blood cells) for transfusion to patients with severe white cell deficiencies are often given a steroid called dexamethasone and a growth factor called G-CSF the day before donation. These drugs stimulate white cell production, allowing many more cells to be collected than would otherwise be possible. A single dose of G-CSF given to healthy people increases their white cells counts by four to five times the next day. It would be preferable, however, to give G-CSF the same day of donation, if possible. Therefore, this study will measure white cell counts in healthy people at various intervals after being injected with G-CSF alone and G-CSF with dexamethasone. The study will compare the following: granulocyte counts at seven different intervals after injection of the drug or drugs; the effects of G-CSF injected through a vein or under the skin; and the effects of giving G-CSF alone or with dexamethasone. Each participant will undergo four procedures, each four weeks apart as follows: donate a small blood sample; receive an injection of G-CSF under the skin or into a vein; and take either two dexamethasone tablets or two placebo tablets. Small blood samples will then be drawn 1, 2, 4, 6, 8, and 24 hours after the drugs are given. Participants will answer questions about how they feel before the drugs are given and at the various intervals after taking the drugs.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)
Treatments:
Dexamethasone
Lenograstim
Sargramostim
Criteria
Male and female subjects.

Must be 18 years of age or older.

Subjects must pass the health criteria for blood donors established by the American
Association of Blood Banks.

No subjects who are pregnant or lactating females.

No subjects with uncontrolled hypertension, heart disease, diabetes, history of allergic
reactions to G-CSF, history of allergic reactions to E. coli, abnormal hemoglobin or white
blood cell counts, a malignancy, asthma, taking prednisone or using an inhalant.

No hemoglobin less than 11.0 or greater than 19.0 gm/dL

No platelet counts less than 140 x 10(9)/L or greater than 500 x 10(9)/L.

No absolute neutrophil count less than 1.5 x 10(9/)/L or greater than 10.0 x 10(9)/L.